NCT06683352: An ongoing trial by Biontech SE
This trial is ongoing. It must report results 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06683352 |
|---|---|
| Title | A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 11, 2024 |
| Completion date | July 15, 2025 |
| Required reporting date | July 15, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |